We report a case of a 60-year-old man with multi-refractory T-LBL exhibiting a partial response to hyper-CVAD followed by progression on venetoclax plus azacitidine. This patient achieved complete remission after a single cycle of DMPD salvage therapy comprising daratumumab, liposomal mitoxantrone, pegaspargase and dexamethasone...It successfully bridged the patient to double umbilical cord blood transplantation, resulting in full donor chimerism by day +21 and sustained remission despite post-transplant complications. The remarkable efficacy observed in this refractory T-LBL case, contrasting sharply with historical treatment outcomes, suggests that the DMPD regimen may serve as both an immediately actionable and potentially definitive therapeutic approach for elderly patients who are ineligible for hematopoietic stem cell transplantation.

23 days ago

Journal

CD7 (CD7 Molecule)

Venclexta (venetoclax) • azacitidine • Darzalex (daratumumab) • dexamethasone • Oncaspar liquid (pegaspargase) • Duoenda (mitoxantrone liposomal)

2ms

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (clinicaltrials.gov)

P=N/A, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

2 months ago

New trial

gemcitabine • Rituxan (rituximab) • ifosfamide • oxaliplatin • etoposide IV • mesna • Duoenda (mitoxantrone liposomal)

2ms

Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR2600117000)

P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine

2 months ago

New trial

Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal) • vindesine

2ms

Clinical Study on the Efficacy and Safety of Zeprumetostat, Azacitidine Combined with Lipo-MIT in Relapsed/Refractory Peripheral T-Cell Lymphoma. (ChiCTR2600116686)

P2, N=26, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

2 months ago

New P2 trial

azacitidine • zeprumetostat (SHR-2554) • Duoenda (mitoxantrone liposomal)

2ms

A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)

P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

2 months ago

New P1/2 trial

Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)

2ms

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (clinicaltrials.gov)

P2, N=26, Recruiting, The First Affiliated Hospital of Soochow University

2 months ago

New P2 trial

azacitidine • zeprumetostat (SHR-2554) • Duoenda (mitoxantrone liposomal)

3ms

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)

P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)

3ms

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) (clinicaltrials.gov)

P1/2, N=43, Not yet recruiting, Sun Yet-Sen University Cancer Center

3 months ago

New P1/2 trial

Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)

4ms

Primary ALK-Negative Anaplastic Large Cell Lymphoma Mimicking Septic Arthritis in a Diabetic Patient: Diagnostic and Therapeutic Challenges. (PubMed, J Vis Exp)

A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.

4 months ago

Journal

ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK negative

etoposide IV • Adcetris (brentuximab vedotin) • Duoenda (mitoxantrone liposomal)

5ms

A prospective multicenter randomized controlled clinical study comparing the efficacy and safety of mitoxantrone hydrochloride liposomes with idarubicin in induction therapy for children with newly diagnosed acute myelocytic leukemia (ChiCTR2500111195)

P=N/A, N=220, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University

5 months ago

New trial

Venclexta (venetoclax) • idarubicin hydrochloride • Duoenda (mitoxantrone liposomal)